D ata for the top prescription drugs of 2011 in the Unites States was recently released by IMS Health, 1 and as we have done each year, 2,3 we will break down the key stats as they apply to CNS therapeutics. Total prescription drug sales in the United States increased from $308.6 billion in 2010 to $319.9 billion in 2011 (an ∼3.5% increase despite pressure from generics), with a concomitant increase in prescriptions dispensed (3.99 billion in 2010 compared to 4.02 billion in 2011).
1 As discussed last year, 3 a combination of generic versus brand medications and a weak economy have negatively impacted prescription drug sales. In parallel, patients continuing on therapies for chronic disease shifted from brand name medications to generic equivalents; thus, the lists of the top 200 drugs in terms of sales and that of prescriptions dispensed share no overlap.
1−4 For example, in 2010, Lipitor was number 1 in terms of sales ($7.3 billion) and number 4 in terms of prescriptions dispensed (∼46 million). With the loss of patent protection in 2011, Lipitor still remained number 1 in terms of sales ($7.7 billion) in 2011 (Table 1) , but Lipitor dropped off the top 25 most prescribed medicines in 2011, while simvastatin, generic Zocor, increased to number 3, with ∼97 million prescriptions dispensed.
1−4
Approximately one-third of the $319.9 billion spent on prescription drugs was focused on only five therapeutic areas (Table 2) : oncology, respiratory agents, lipid regulators, antidiabetics, and antipsychotics.
1 Despite a growing trend of big pharma leaving CNS drug discovery, antipsychotics continue to grow, with $18.2 billion in sales in 2011, up $2.1 billion over 2010. In 2011, 57 million prescriptions were filled for antipsychotic drugs, up 2.4%, and, importantly, ∼60% were filled with branded drugs. Overall, CNS drugs rank high in terms of both sales and prescriptions dispensed in the United States in 2011 (Tables  1−3 ). Beyond 2012, generic competition for antipsychotics, antidepressants, and other CNS therapeutics further underscores the need for the development of therapeutic agents with novel mechanisms of actions/novel molecular targets. When one looks at the trends and medications, the United States is suffering from poor lifestyle/diet choices (based on sales of lipid regulators and antidiabetic medications) and an unprecedented increase in patients taking antidepressants and antipsychotics. Importantly, increases in both sales and prescriptions dispensed are positive signs for a struggling pharmaceutical industry. 
